ArticleInternational journal of chronic obstructive pulmonary disease2017
"Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.
Article in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Withdrawal of Inhaled Corticosteroids from Patients with COPD; Effect on Exacerbation Frequency and Lung Function: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2024Pooled it
- In 'real world' patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations.Respiratory research · 2023Article
- A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients.NPJ primary care respiratory medicine · 2022Article
- Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.Respiratory research · 2022Article
- Implementation of a Targeted Inhaled Corticosteroid De-Escalation Process in Patients with Chronic Obstructive Pulmonary Disease in the Primary Care Setting.Innovations in pharmacy · 2022Article
- Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain.International journal of chronic obstructive pulmonary disease · 2022Observational
- Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study.Respiratory research · 2021Observational
- Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Benefits and Risks.Clinics in chest medicine · 2020Review
- Stable Clinical Course of Chronic Obstructive Pulmonary Disease Patients in the Era of Double Bronchodilator Therapy: A Single Referral Center Experience.Journal of clinical medicine · 2020Article
- Deprescribing in older people.Australian prescriber · 2020Review
- Treatment of COPD and COPD-heart failure comorbidity in primary care in different stages of the disease.Primary health care research & development · 2020Observational
- Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy.International journal of chronic obstructive pulmonary disease · 2020Review
- Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline.International journal of chronic obstructive pulmonary disease · 2020Article
- Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study.International journal of chronic obstructive pulmonary disease · 2020Article
- Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study.ERJ open research · 2020Article
- A Simplified Algorithm for the Diagnosis, Treatment, and Management of COPD in Routine Primary Care Practice.International journal of chronic obstructive pulmonary disease · 2020Article
- Are there specific clinical characteristics associated with physician's treatment choices in COPD?Respiratory research · 2019Article
- Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status.European journal of clinical pharmacology · 2019Article
- The Airways' Mechanical Stress in Lung Disease: Implications for COPD Pathophysiology and Treatment Evaluation.Canadian respiratory journal · 2019Review
- A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management.International journal of chronic obstructive pulmonary disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients with chronic obstructive pulmonary disease (COPD) receive inhaled corticosteroids (ICSs) without a clear indication, and thus, the impact of ICS withdrawal on disease control is of great interest. DACCORD is a prospective, noninterventional 2-year study in the primary and secondary care throughout Germany. A subgroup of patients were taking ICS prior to entry - 1,022 patients continued to receive ICS for 2 years; physicians withdrew ICS on entry in 236 patients. Data from these two subgroups were analyzed to evaluate the impact of ICS withdrawal. Patients aged ≥40 years with COPD, initiating or changing COPD maintenance medication were recruited, excluding patients with asthma. Demographic and disease characteristics, prescribed COPD medication, COPD Assessment Test, exacerbations, and lung function were recorded. There were few differences in baseline characteristics; ICS withdrawn patients had shorter disease duration and better lung function, with 74.2% of ICS withdrawn patients not exacerbating, compared with 70.7% ICS-continued patients. During Year 1, exacerbation rates were 0.414 in the withdrawn group and 0.433 in the continued group. COPD Assessment Test total score improved from baseline in both groups. These data suggest that ICS withdrawal is possible with no increased risk of exacerbations in patients with COPD managed in the primary and secondary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.